Psychopharmacology and Psychiatry Updates

In this episode, we explore the newly published INTEGRATE guidelines—the first truly international algorithm for schizophrenia treatment. Should clozapine be started after just 12 weeks? When are long-acting injectables appropriate for first-episode patients? Discover how these guidelines aim to standardize quality care worldwide. Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 77 INTEGRATE: New Schizophrenia Treatment Guidelines

In this episode, we explore the practical role of genetic testing in psychiatry with Dr. Chris Aiken. Which genetic tests actually matter in clinical practice? We cut through the marketing hype to reveal the three essential pharmacokinetic tests and FDA requirements that can prevent serious adverse events in your patients. Faculty: Chris Aiken, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: The Role of Genetic Testing in Psychiatry Pharmacogenetic Tests That Matter in Psychiatric Practice

In this episode, we explore a head-to-head comparison of lithium versus quetiapine augmentation for treatment-resistant depression. When patients have failed multiple antidepressants, which augmentation strategy offers the best balance of efficacy and tolerability? We examine real-world data tracking symptom burden and side effects over an entire year. Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 76 Treatment-Resistant Depression: Lithium vs. Quetiapine for Augmentation?

In this episode, we explore pharmacologic strategies for postpartum psychosis with insights from Dr. Lauren Osborne, focusing on a critical clinical question: Can we safely use mood stabilizers like lithium in breastfeeding mothers with bipolar disorder? Discover evidence-based guidance for navigating this high-stakes decision when maternal mental health hangs in the balance. Faculty: Lauren Osborne, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Understanding Postpartum Mood Disorders: A Comprehensive Guide Postpartum Psychosis: Pharmacologic Strategies

In this episode, we explore brexanolone and zuranolone—the first FDA-approved medications specifically for postpartum depression. How do these neurosteroid-based treatments work differently than traditional antidepressants, and could they offer relief in just days rather than weeks? Faculty: Lauren Osborne, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Understanding Postpartum Mood Disorders: A Comprehensive Guide The Role of Brexanolone and Zuranolone in Postpartum Depression